Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Presentation Update

<< Previous

Bullboard Posts

Next >>

Post by Wino115on Jul 19, 2022 4:30pm

177 Views

Post# 34835482

Presentation Update

Looks like the new version will be coming soon. All presentations down.

Suggestion to IR. Start building a more robust, citation heavy case around the function, value and benefit of sortilin. It's an unknown target but there is tons of highly detailed academic studies pointing to its value and prospective moth as an oncology target. Start the education process.

<< Previous

Bullboard Posts

Next >>

Increasing summer travel could see these airline stocks soar